Hence, it is reasonable to suggest that targeting these pro-fibrotic factors with CTGF, TGF-β, RAAS, Gal-3, NLRP3, and βAR inhibitors can be a promising approach for the treatment of myocardial fibrosis after cardiac tissue damage/remodeling. This evidence concerns the gene LGALS3 and Myocardial fibrosis.